Phase 3 Randomized Low-Dose Paclitaxel Chemoradiotherapy Study for Locally Advanced Non-Small Cell Lung Cancer
| Autor: | Rong Yu, Kishan J. Pandya, Yingjie Wang, Guangying Zhu, Yuhchyau Chen, Yannan Yuan, Linchun Feng, Huimin Ma, Jiancheng Li, Hang Li, Jianhao Geng, Tingyi Xia, Hongmei Lin, Anhui Shi |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2016 |
| Předmět: |
0301 basic medicine
Cancer Research medicine.medical_specialty phase 3 trial medicine.medical_treatment Urology Phases of clinical research Neutropenia lcsh:RC254-282 chemoradiotherapy 03 medical and health sciences paclitaxel 0302 clinical medicine medicine Clinical endpoint Lung cancer non-small cell lung cancer Chemotherapy business.industry Standard treatment Hazard ratio lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens medicine.disease Clinical Trial Surgery 030104 developmental biology Oncology 030220 oncology & carcinogenesis radiosensitization business Chemoradiotherapy |
| Zdroj: | Frontiers in Oncology Frontiers in Oncology, Vol 6 (2016) |
| ISSN: | 2234-943X |
| DOI: | 10.3389/fonc.2016.00260 |
| Popis: | Introduction Concurrent chemoradiotherapy (CCRT) is the standard treatment for locally advanced non-small cell lung cancer (LA-NSCLC) but is associated with poor chest tumor control. Here, we report results of a randomized phase 3 study comparing two CCRT regimens in improving chest tumor control by low-dose paclitaxel chemoradiation for LA-NSCLC. Methods Due to the logistics of local referral pattern, the study was designed to enroll patients with stage III LA-NSCLC who had completed 2–4 cycles of full-dose chemotherapy. One hundred thirty four were randomized to either Arm 1 [paclitaxel at 15 mg/m2, three times per week (Monday, Wednesday, and Friday) for 6 weeks, n = 74] or Arm 2 (weekly paclitaxel at 45 mg/m2 for 6 weeks, n = 60). Chest radiotherapy was 60–70 Gy in standard fractionation. Response rate was the primary endpoint, with recurrence-free survival (RFS) as the secondary endpoint. Results From March 2006 to February 2013, 71 patients completed Arm 1 treatment and 59 completed Arm 2 treatment. The response rate for Arm 1 was significantly higher (83.1%) than Arm 2 (54.2%) (p=0.001). RFS was superior in Arm 1: median 14.6 vs. 9.4 months, p = 0.005, Hazard ratio (HR) 1.87 [95% confidence interval (CI) 1.20, 2.90]. Overall survival was not significantly different: median 32.6 months in Arm 1 vs. 31.3 months in Arm 2, p = 0.91, HR 0.97 (95% CI 0.55, 1.70). Toxicity was significantly lower in Arm 1 for Grade 3 and 4 leukopenia/neutropenia (p |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|